Phlox Therapeutics raised €1.9M in a seed funding round led by ROM Utrecht Region to advance its RNA therapies for genetic laminopathies.

Nov 13, 2024•about 1 year ago

Amount Raised

€1.9 Million

Round Type

seed

NaardenGeneticsTherapeuticsBiotechnologyHealth Care

Investors

Hubrecht InstituteDutch Research Council (Nwo)Utrecht Health Seed Fund (Uhsf)Amsterdam Umc Venture HoldingFirst Fund (Managed By Bgv)Rom Utrecht Region

Description

Naarden-based Phlox Therapeutics has raised €1.9M in funding to advance its RNA therapies for genetic laminopathies. The funding round includes ROM Utrecht Region and other existing investors, with additional non-dilutive investment from the Dutch Research Council.

Company Information

Company

Phlox Therapeutics

Location

Naarden, North Holland, Netherlands

About

Phlox Therapeutics is a biotechnology company founded in 2022 that specializes in developing RNA-based gene therapies to treat genetic laminopathies and cardiomyopathies. The company focuses on targeting genetic mutations associated with these conditions, aiming to improve patient outcomes. By advancing its RNA technology, Phlox aims to become a key player in next-generation RNA therapies for genetic heart diseases. Their work seeks to address currently untreatable genetic conditions and improve treatment options for patients.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns